부산대학교 도서관

Many of the highest priority targets in a wide range of disease states are difficult‐to‐drug proteins. The development of reversible small molecule inhibitors for the active sites of these proteins with sufficient affinity and residence time on‐target is an enormous challenge. This has engendered interest in strategies to increase the potency of a given protein inhibitor by routes other than further improvement in gross affinity. Amongst these, the development of catalytic protein inhibitors has garnered the most attention and investment, particularly with respect to protein degraders, which catalyze the destruction of the target protein. This article discusses the genesis of the burgeoning field of catalytic inhibitors, the current state of the art, and exciting future directions. [ABSTRACT FROM AUTHOR]